ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1947

Thy1 Is a Positive Regulator of Osteoblast Differentiation and Modulates Bone Homeostasis in Obese Mice

Ananta Paine1, Collynn Woeller2, Nelson Huertas1, Maria de la Luz Garcia-Hernandez3, Richard Phipps2 and Christopher T. Ritchlin4, 1Department of Medicine, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, 2Department of Environmental Medicine, School of Medicine and Dentistry,, Department of Environmental Medicine, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, 3Department of Medicine,, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, 4Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: bone biology, obesity, Osteoarthritis, osteoblasts and stem cells

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Biology and Pathology of Bone and Joint Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Thy1 (CD90) is a glycosylated, glycophosphatidylinositol (GPI)-anchored membrane protein originally identified as a marker for mouse T cells but subsequent reports noted expression on stem cells, osteoblasts and fibroblasts. Thy1 is abundantly expressed by mesenchymal stem cells and inhibits adipogenesis. We examined the contribution of Thy1 to osteoblastogenesis and bone homeostasis.

Methods: A pre-osteoblastic MC3T3 cell line, and primary bone marrow derived mesenchymal stem cells from wild type (WT) C57BL/6 mice were cultured in osteogenic conditions for up to 21 days. Messenger RNA (mRNA) and protein expression of Thy1 and the OB differentiation markers RUNX2, BGLAP, COL1A1, were analyzed by real-time PCR and western blot. Similarly, mouse embryonic fibroblasts (MEFs) isolated from WT and Thy1 knockout (KO) mice were cultured in osteogenic media. Mineralized matrix and calcium deposition were examined with alizarin red staining. To study the impact of Thy1 depletion on bone quality in the normal and obese mice, 2 month old C57BL/6 WT and Thy1 KO mice were fed a normal or high fat diet for 2 months and long bones were analyzed with micro-CT to compare changes in bone architecture and overall bone quality.

Results: In vitro assays revealed that osteogenic conditions transiently increased Thy1 expression during OB differentiation. In vitro experiments with WT and Thy1 KO mesenchymal cells and MEFs further revealed that in the absence of Thy1, osteoblastogenesis was delayed as noted by alizarin red staining. Micro CT analysis of long bones in WT and Thy1 KO mice revealed that when Thy1 KO and WT mice were fed a high fat diet, bone quality at 4 months differed significantly between WT and KO mice. In particular, a significant reduction in trabecular bone quality was noted in Thy1 KO mice. The most significant differences were seen in tibial trabecular bone volume/total volume (BV/TV): 0.12 ± 0.02 in WT vs 0.09± 0.01 in Thy1 KO, (p < 0.03), femoral BV/TV: 0.37± 0.15 in WT vs. 0.19 ± 0.03 in Thy1 KO femur, (p < 0.03) and tibial trabecular bone connectivity density: 50.01± 10.85 in WT vs 28.29± 6.72 in Thy1 KO, (p <0.01), and femoral trabecular bone connectivity density: 42.03±14.42 in WT vs. 22.17±7.79 in Thy1 KO femur, (p <0.019); overall more than a 40% decrease. Interestingly, significant differences were not detected in WT and Thy1 KO mice fed a normal diet.

Conclusion: We find that Thy1 is required for differentiation of OB based on our in vitro experiments. Absence or decreased expression of Thy1 was associated with reduced bone quality. Of note, higher levels of Thy1 mRNA and protein levels were reported in osteoarthritis patients, a disease characterized by osteophyte formation with higher prevalence in obese individuals. Thus, Thy1 may serve as an important mechanistic link between bone formation and obesity.


Disclosure: A. Paine, None; C. Woeller, None; N. Huertas, None; M. D. L. L. Garcia-Hernandez, None; R. Phipps, None; C. T. Ritchlin, UCB, 2,abbvie, 2,Amgen, 2,Amgen, 5,Abbvie, 5,Janssen Pharmaceutica Product, L.P., 5,Novartis Pharmaceutical Corporation, 5,Pfizer Inc, 5.

To cite this abstract in AMA style:

Paine A, Woeller C, Huertas N, Garcia-Hernandez MDLL, Phipps R, Ritchlin CT. Thy1 Is a Positive Regulator of Osteoblast Differentiation and Modulates Bone Homeostasis in Obese Mice [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/thy1-is-a-positive-regulator-of-osteoblast-differentiation-and-modulates-bone-homeostasis-in-obese-mice/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/thy1-is-a-positive-regulator-of-osteoblast-differentiation-and-modulates-bone-homeostasis-in-obese-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology